Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
Shares in California, USA-based autoimmune specialist Annexon soared more than 37% in pre-market trading on Tuesday to $6.32, after it announced positive top-line results from its randomized placebo-controlled pivotal Phase III trial in patients with Guillain-Barré syndrome (GBS). 5 June 2024
Biotechnology
Florida, USA-based Summit Therapeutics has managed to beat the leading checkpoint blocker, Keytruda (pembrolizumab), in a head-to-head comparison. 4 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
BridgeBio Pharma’s (Nasdaq: BBIO) shares were up nearly 5% at $30.37 in early trading, after the company announced sustained positive results from PROPEL 2. 4 June 2024
Biotechnology
Israel-based artificial intelligence (AI) focused biotech Biolojic Design has entered into a multi-target drug discovery collaboration with Germany’s Merck KGaA. 4 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Biotechnology
Cambridge, USA-based Agios Pharmaceuticals last week agreed to sell its royalty rights on Servier’s sales of vorasidenib for up to $1.1 billion to Royalty Pharma. US pharma giant Merck & Co last Wednesday announced its intention to acquire EyeBio for up to $3 billion along with its ophthalmology pipeline. On the research front, biotech Insmed announced positive Phase III results for its bronchiectasis candidate brensocatib. Human Immunology Biosciences (HI-Bio), the subject of a $1.8 billion takeover bid from Biogen, released positive results for its CD38 antibody felzartamab in the treatment of IgA nephropathy. Also, Gilead Sciences released Ph III trial results for Trodelvy in bladder cancer, which failed to meet its primary endpoint. 2 June 2024
Biotechnology
Biotech firm Moderna has won US Food and Drug Administration (FDA) approval for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. 31 May 2024
Biotechnology
A strategic partnership between Germany’s BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) is to be expanded. 31 May 2024
Biotechnology
Autoimmune diseases specialist Immunovant has opted to prioritize the development of IMVT-1402 as its lead asset due to its broad potential across a number of indications. 31 May 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze